Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
ANIK's Cash to Debt is ranked higher than
97% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. ANIK: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANIK' s Cash to Debt Range Over the Past 10 Years
Min: 1.66  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.93
ANIK's Equity to Asset is ranked higher than
90% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ANIK: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
ANIK' s Equity to Asset Range Over the Past 10 Years
Min: 0.49  Med: 0.78 Max: 0.94
Current: 0.93
0.49
0.94
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
96% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANIK' s Interest Coverage Range Over the Past 10 Years
Min: 38.66  Med: 5127.88 Max: No Debt
Current: No Debt
F-Score: 8
Z-Score: 27.71
M-Score: -2.30
WACC vs ROIC
14.30%
43.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 52.05
ANIK's Operating margin (%) is ranked higher than
97% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. ANIK: 52.05 )
Ranked among companies with meaningful Operating margin (%) only.
ANIK' s Operating margin (%) Range Over the Past 10 Years
Min: 11.81  Med: 21.47 Max: 58.19
Current: 52.05
11.81
58.19
Net-margin (%) 33.64
ANIK's Net-margin (%) is ranked higher than
93% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. ANIK: 33.64 )
Ranked among companies with meaningful Net-margin (%) only.
ANIK' s Net-margin (%) Range Over the Past 10 Years
Min: 7.77  Med: 16.82 Max: 36.29
Current: 33.64
7.77
36.29
ROE (%) 17.32
ANIK's ROE (%) is ranked higher than
92% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. ANIK: 17.32 )
Ranked among companies with meaningful ROE (%) only.
ANIK' s ROE (%) Range Over the Past 10 Years
Min: 5.16  Med: 11.29 Max: 24.43
Current: 17.32
5.16
24.43
ROA (%) 15.75
ANIK's ROA (%) is ranked higher than
94% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. ANIK: 15.75 )
Ranked among companies with meaningful ROA (%) only.
ANIK' s ROA (%) Range Over the Past 10 Years
Min: 3.27  Med: 7.61 Max: 21.97
Current: 15.75
3.27
21.97
ROC (Joel Greenblatt) (%) 77.78
ANIK's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. ANIK: 77.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANIK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 13.35  Med: 40.48 Max: 110.18
Current: 77.78
13.35
110.18
Revenue Growth (3Y)(%) 6.90
ANIK's Revenue Growth (3Y)(%) is ranked higher than
55% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ANIK: 6.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANIK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.4  Med: 7.5 Max: 26.9
Current: 6.9
-4.4
26.9
EBITDA Growth (3Y)(%) 26.10
ANIK's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. ANIK: 26.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANIK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.4  Med: 32.2 Max: 91.7
Current: 26.1
-64.4
91.7
EPS Growth (3Y)(%) 34.80
ANIK's EPS Growth (3Y)(%) is ranked higher than
86% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ANIK: 34.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANIK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.3  Med: 29.75 Max: 72.4
Current: 34.8
-64.3
72.4
» ANIK's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-07-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ANIK Guru Trades in Q4 2015

Chuck Royce 59,265 sh (New)
Ken Fisher 14,124 sh (New)
Jim Simons 113,000 sh (+110.82%)
Joel Greenblatt 104,446 sh (+17.11%)
» More
Q1 2016

ANIK Guru Trades in Q1 2016

Paul Tudor Jones 4,911 sh (New)
Ken Fisher 57,719 sh (+308.66%)
Jim Simons 300,400 sh (+165.84%)
Joel Greenblatt 163,108 sh (+56.16%)
Chuck Royce 46,465 sh (-21.60%)
» More
Q2 2016

ANIK Guru Trades in Q2 2016

Joel Greenblatt 198,303 sh (+21.58%)
Ken Fisher 57,719 sh (unchged)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jim Simons 271,100 sh (-9.75%)
» More
Q3 2016

ANIK Guru Trades in Q3 2016

Paul Tudor Jones 12,831 sh (New)
Ken Fisher 93,715 sh (+62.36%)
Jim Simons 207,700 sh (-23.39%)
Joel Greenblatt 79,286 sh (-60.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3841
Compare:NAS:EPZM, NAS:GBT, NAS:CLCD, NAS:ANIP, NAS:KERX, NAS:LOXO, NAS:ARDX, NAS:PACB, NAS:NTLA, NAS:AMRI, NAS:NK, OTCPK:BPMUF, NAS:PGNX, NAS:VTAE, NAS:ACHN, NAS:VNDA, OTCPK:SNBIF, NAS:RPTP, NAS:ACRS, NAS:CERS » details
Traded in other countries:AKP.Germany,
Anika Therapeutics Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. The Company through its subsidiary has over 20 products currently commercialized, mainly in Europe.

Anika Therapeutics Inc was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through its subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents,therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are Merogel, a woven fleece nasal

Top Ranked Articles about Anika Therapeutics Inc

Top Medical Companies Reach High Financial Strength A study of Altman Z-scores, Part 3: NYSE and Nasdaq companies have wider scores
Among all stocks trading on the New York Stock Exchange and Nasdaq, two medical companies, Intuitive Surgical Inc. (NASDAQ:ISRG) and Anika Therapeutics Inc. (NASDAQ:ANIK), have relatively strong Altman Z-scores. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.12
ANIK's P/E(ttm) is ranked higher than
63% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. ANIK: 21.12 )
Ranked among companies with meaningful P/E(ttm) only.
ANIK' s P/E(ttm) Range Over the Past 10 Years
Min: 8.57  Med: 20.01 Max: 46.32
Current: 21.12
8.57
46.32
Forward P/E 21.69
ANIK's Forward P/E is ranked lower than
56% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. ANIK: 21.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.12
ANIK's PE(NRI) is ranked higher than
65% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. ANIK: 21.12 )
Ranked among companies with meaningful PE(NRI) only.
ANIK' s PE(NRI) Range Over the Past 10 Years
Min: 8.57  Med: 20.01 Max: 46.32
Current: 21.12
8.57
46.32
Price/Owner Earnings (ttm) 28.95
ANIK's Price/Owner Earnings (ttm) is ranked higher than
51% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. ANIK: 28.95 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ANIK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.69  Med: 27.66 Max: 450.83
Current: 28.95
12.69
450.83
P/B 3.38
ANIK's P/B is ranked higher than
55% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ANIK: 3.38 )
Ranked among companies with meaningful P/B only.
ANIK' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 2.43 Max: 4.63
Current: 3.38
0.58
4.63
P/S 7.13
ANIK's P/S is ranked higher than
63% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. ANIK: 7.13 )
Ranked among companies with meaningful P/S only.
ANIK' s P/S Range Over the Past 10 Years
Min: 1  Med: 3.92 Max: 9.14
Current: 7.13
1
9.14
PFCF 55.83
ANIK's PFCF is ranked lower than
75% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. ANIK: 55.83 )
Ranked among companies with meaningful PFCF only.
ANIK' s PFCF Range Over the Past 10 Years
Min: 10.44  Med: 20.35 Max: 1111.54
Current: 55.83
10.44
1111.54
POCF 22.55
ANIK's POCF is ranked lower than
53% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. ANIK: 22.55 )
Ranked among companies with meaningful POCF only.
ANIK' s POCF Range Over the Past 10 Years
Min: 8.89  Med: 18.59 Max: 1073.75
Current: 22.55
8.89
1073.75
EV-to-EBIT 10.91
ANIK's EV-to-EBIT is ranked higher than
69% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. ANIK: 10.91 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIK' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 10.55 Max: 37.9
Current: 10.91
1.8
37.9
EV-to-EBITDA 10.17
ANIK's EV-to-EBITDA is ranked higher than
70% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. ANIK: 10.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.4  Med: 9.15 Max: 34
Current: 10.17
1.4
34
PEG 0.53
ANIK's PEG is ranked higher than
87% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. ANIK: 0.53 )
Ranked among companies with meaningful PEG only.
ANIK' s PEG Range Over the Past 10 Years
Min: 0.29  Med: 0.6 Max: 30.56
Current: 0.53
0.29
30.56
Shiller P/E 44.90
ANIK's Shiller P/E is ranked higher than
53% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. ANIK: 44.90 )
Ranked among companies with meaningful Shiller P/E only.
ANIK' s Shiller P/E Range Over the Past 10 Years
Min: 14.29  Med: 39.6 Max: 113.22
Current: 44.9
14.29
113.22
Current Ratio 21.22
ANIK's Current Ratio is ranked higher than
93% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ANIK: 21.22 )
Ranked among companies with meaningful Current Ratio only.
ANIK' s Current Ratio Range Over the Past 10 Years
Min: 2.91  Med: 7.04 Max: 23.7
Current: 21.22
2.91
23.7
Quick Ratio 18.85
ANIK's Quick Ratio is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. ANIK: 18.85 )
Ranked among companies with meaningful Quick Ratio only.
ANIK' s Quick Ratio Range Over the Past 10 Years
Min: 2.19  Med: 6.07 Max: 21.67
Current: 18.85
2.19
21.67
Days Inventory 250.19
ANIK's Days Inventory is ranked lower than
78% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. ANIK: 250.19 )
Ranked among companies with meaningful Days Inventory only.
ANIK' s Days Inventory Range Over the Past 10 Years
Min: 98.12  Med: 146.3 Max: 250.19
Current: 250.19
98.12
250.19
Days Sales Outstanding 75.50
ANIK's Days Sales Outstanding is ranked lower than
60% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. ANIK: 75.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.73  Med: 88.04 Max: 109.78
Current: 75.5
47.73
109.78
Days Payable 31.23
ANIK's Days Payable is ranked lower than
69% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ANIK: 31.23 )
Ranked among companies with meaningful Days Payable only.
ANIK' s Days Payable Range Over the Past 10 Years
Min: 20.94  Med: 62.17 Max: 169.68
Current: 31.23
20.94
169.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
ANIK's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ANIK: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANIK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.5  Med: -2.5 Max: -0.2
Current: -2.7
-26.5
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.99
ANIK's Price/Net Cash is ranked lower than
54% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. ANIK: 6.99 )
Ranked among companies with meaningful Price/Net Cash only.
ANIK' s Price/Net Cash Range Over the Past 10 Years
Min: 0.48  Med: 6.96 Max: 79.94
Current: 6.99
0.48
79.94
Price/Net Current Asset Value 5.02
ANIK's Price/Net Current Asset Value is ranked higher than
57% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. ANIK: 5.02 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANIK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.34  Med: 4.51 Max: 40.16
Current: 5.02
0.34
40.16
Price/Tangible Book 3.71
ANIK's Price/Tangible Book is ranked higher than
59% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ANIK: 3.71 )
Ranked among companies with meaningful Price/Tangible Book only.
ANIK' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 2.76 Max: 13.3
Current: 3.71
0.29
13.3
Price/Projected FCF 1.60
ANIK's Price/Projected FCF is ranked higher than
72% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. ANIK: 1.60 )
Ranked among companies with meaningful Price/Projected FCF only.
ANIK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.9 Max: 17.71
Current: 1.6
0.48
17.71
Price/DCF (Earnings Based) 0.78
ANIK's Price/DCF (Earnings Based) is ranked higher than
70% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ANIK: 0.78 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.83
ANIK's Price/Median PS Value is ranked lower than
81% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ANIK: 1.83 )
Ranked among companies with meaningful Price/Median PS Value only.
ANIK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.05 Max: 2.32
Current: 1.83
0.12
2.32
Price/Peter Lynch Fair Value 0.85
ANIK's Price/Peter Lynch Fair Value is ranked higher than
80% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. ANIK: 0.85 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ANIK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.37  Med: 0.81 Max: 5.53
Current: 0.85
0.37
5.53
Price/Graham Number 1.87
ANIK's Price/Graham Number is ranked higher than
63% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. ANIK: 1.87 )
Ranked among companies with meaningful Price/Graham Number only.
ANIK' s Price/Graham Number Range Over the Past 10 Years
Min: 0.49  Med: 1.7 Max: 7.69
Current: 1.87
0.49
7.69
Earnings Yield (Greenblatt) (%) 9.17
ANIK's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. ANIK: 9.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANIK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.6  Med: 9.5 Max: 56.4
Current: 9.17
2.6
56.4
Forward Rate of Return (Yacktman) (%) 31.08
ANIK's Forward Rate of Return (Yacktman) (%) is ranked higher than
77% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. ANIK: 31.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANIK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.2  Med: 16.3 Max: 54.6
Current: 31.08
-11.2
54.6

More Statistics

Revenue (TTM) (Mil) $105.5
EPS (TTM) $ 2.33
Beta1.59
Short Percentage of Float6.44%
52-Week Range $35.07 - 54.96
Shares Outstanding (Mil)14.62

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 103 117 123
EPS ($) 2.01 2.13 2.15
EPS w/o NRI ($) 2.01 2.13 2.15
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for ANIK

Headlines

Articles On GuruFocus.com
Top Medical Companies Reach High Financial Strength Jul 19 2016 
Four Stocks With Growing EPS Near Their 52-Week Lows - Part II Jul 02 2015 
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Nov 03 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Anika Therapeutics, Inc. (ANIK) Hedge Funds Are Snapping Up Dec 09 2016
Roche Presents Positive Follicular Lymphoma Data on Gazvya Dec 06 2016
Cytori Scleroderma Study Two-Year Follow-Up Data Published Nov 30 2016
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease Nov 30 2016
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial Nov 29 2016
Zacks.com featured highlights: Chemours, Matador Resources, Best Buy, Anika Therapeutics and... Nov 25 2016
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health Nov 25 2016
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S. Nov 25 2016
Glaxo Nucala Favorable in Rare Vasculitis Disease Study Nov 24 2016
Juno's ROCKET Study on Clinical Hold Again, Shares Down Nov 24 2016
Bristol-Myers' Opdivo Gets EU Approval for Label Expansion Nov 23 2016
AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials Nov 23 2016
Allergan's Fibristal Approved in Canada for Label Expansion Nov 22 2016
Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : November... Nov 22 2016
Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017 Nov 21 2016
Novartis/Amgen Migraine Drug Positive in Phase III Study Nov 18 2016
Keryx (KERX) Stock Up on Positive Phase III Auryxia Data Nov 18 2016
Regeneron/Sanofi's Praluent CV Outcomes Study to Continue Nov 18 2016
Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta Nov 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)